CHR Citadelle Liège
Liège, 4000, Belgium
Location status: Recruiting
NCT Number: NCT06229769
This study is a 9-year natural history study for patients with Angelman syndrome in Belgium (a genetic neurodevelopmental disorder, affecting 500,000 individuals in the world). It includes a 3-year recruitment phase, a 5 year follow-up and a year to analyze the collected data. The investigators plan to include 30 patients with a semi-annual follow-up for 4 years.
The investigators will collect relevant retrospective and prospective data using age-standardized scales and questionnaires for functional motor assessments and global developmental assessment.
Interested in participating?
Request InfoAll sexes
Observational
Patients are seen every six months for five years. In these visits, patient have medical review (general medical examination, neurological examination), vital signs (height, weight, respiratory rate, heart rate, blood pressure), cognitive assessment (Bayley-IV), language assessment and questionaire (Bayley-IV, ORCA), motor assessments (Bayley-IV, FMS, Developmental milestones and HINE), quality of life questionnaire (PedsQL, CGI-CASS) and general development questionnaire (Vineland-II).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years
Scale of 58 items of Gross motor (raw score 0 to 116) development evaluation.
Time frame: 2 years
Scale of 46 items of fine motor scale (raw score 0 to 92) development evaluation.
Time frame: 2 years
Scale of 81 items of cognitive scale development evaluation (raw score 0 to 162).
Time frame: 2 years
Scale of 42 items of receptive communication abilities scale in development evaluation (raw score 0 to 84).
Time frame: 2 years
Scale of 37 items of expressive communication abilities scale in development evaluation (raw score 0 to 74).
Time frame: 2 years
Scale o 3 items (5, 50 and 500 meters distance of ability to move alone) to classify children's functional mobility, document change over time in the same child and to document change seen following. This scale is scored 1 (moving alone with wheelchair) to 6 (running).
Time frame: 2 years
Scale to Evaluate the general gross motor milestones of 6 items global motor ability, from ability to sit without support to walk alone (score by able or not able). .
Time frame: 2 years
Scale of 8 items to evaluation the mobility in young children, scored 0 (unable) to 4 (able and normal for children age) per items (total raw score from 0 to 32).
Time frame: 2 years
11 subscales of items evaluated with Caregivers interview tool for assessing the level of autonomy and adaptation for all ages.
Subscales are composed as following (higher scores with better the abilites):
Time frame: 2 years
Caregivers interview of 23 items with subscales to assessing the general communication.
This is a qualitative questionnaire.
Time frame: 2 years
To improve the design of future clinical trials by validating tools of assessment based on their suitability to be used as prognostic measures.
Time frame: 2 years
Caregivers interview of quality of life severity and change in patient with Angelman Syndrome since last 7 days and since the last month.
Part regarding the severity in last 7 days is composed of 9 items scored 0 ("not at all difficult") to 4 ("very difficult"), raw score is between 0 to 36.
Part regarding change in last month is composed of 9 items scored 1 ("very much improved") to 7 ("very much worse"), raw score is between 0 to 63,
Time frame: 2 years
Caregivers interview of quality of life and family impact in daily life separated in two parts, one regarding the last 7 days and one regarding the last month.
Total raw score for each part is on 100 (100 related to no impact to 0 related to a huge impact).
Time frame: 1 year
To create a DNA biobank
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire de Liege
Other
A Monocentric, Prospective, Longitudinal and Observational Natural History Study for Patients With Angelman Syndrome in CHR Citadelle Liège : NatHis-Angelman
Acronym: NatHisAngelman
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07605429
Abnormalities, Multiple, Angelman Syndrome
San Diego, California, United States
View Trial DetailsNCT07157254
Abnormalities, Multiple, Angelman Syndrome
Los Angeles, California, United States
View Trial DetailsNCT07181837
Abnormalities, Multiple, Angelman Syndrome
Los Angeles, California, United States
View Trial DetailsNCT06914609
Abnormalities, Multiple, Angelman Syndrome
Los Angeles, California, United States
View Trial Details